title: Systematic review and meta-analysis of linezolid and daptomycin for treatment of vancomycin-resistant enterococcal bloodstream infections.
abstract: Bloodstream infections due to vancomycin-resistant enterococci (VRE-BSI) result in substantial patient mortality and cost. Daptomycin and linezolid are commonly prescribed for VRE-BSI, but there are no clinical trials to determine optimal antibiotic selection. We conducted a systematic review for investigations that compared daptomycin and linezolid for VRE-BSI. We searched Medline from 1966 through 2012 for comparisons of linezolid and daptomycin for VRE-BSI. We included searches of EMBASE, clinicaltrials.gov, and national meetings. Data were extracted using a standardized instrument. Pooled odds ratios (OR) and 95% confidence intervals (95% CI) were calculated using a fixed-effects model. Our search yielded 4,243 publications, of which 482 contained data on VRE treatment. Most studies (452/482) did not present data on BSI or did not provide information on linezolid or daptomycin. Among the remaining 30 studies, 9 offered comparative data between the two agents. None were randomized clinical trials. There was no difference in microbiologic (n = 5 studies, 517 patients; OR, 1.0; 95% CI, 0.4 to 1.7; P = 0.95) and clinical (n = 3 studies, 357 patients; OR, 1.2; 95% CI, 0.7 to 2.0; P = 0.7) cures between the two antibiotics. There was a trend toward increased survival with linezolid compared to daptomycin treatment (n = 9 studies, 1,074 patients; OR, 1.3; 95% CI, 1.1 to 1.8; I(2) = 0 [where I(2) is a measure of inconsistency]), but this did not reach statistical significance (P = 0.054). There are limited data to inform clinicians on optimal antibiotic selection for VRE-BSI. Available studies are limited by small sample size, lack of patient-level data, and inconsistent outcome definitions. Additional research, including randomized clinical trials, is needed before conclusions can be drawn about treatment options for VRE therapy.
authors.affiliation: Infectious Disease Clinical Outcomes Research Unit, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, California, USA.
authors.forename: Donald W
authors.initials: DW
authors.lastname: Whang
authors.forename: Loren G
authors.initials: LG
authors.lastname: Miller
authors.forename: Neil M
authors.initials: NM
authors.lastname: Partain
authors.forename: James A
authors.initials: JA
authors.lastname: McKinnell
mesh_terms: D000081:Acetamides / Q000627:therapeutic use*; D016470:Bacteremia / Q000188:drug therapy*; D017576:Daptomycin / Q000627:therapeutic use*; D016983:Enterococcus / Q000187:drug effects* / Q000472:pathogenicity*; D006801:Humans; D000069349:Linezolid; D023303:Oxazolidinones / Q000627:therapeutic use*; D020713:Vancomycin Resistance
chemical_list: D000081:Acetamides; D023303:Oxazolidinones; D000069349:Linezolid; D017576:Daptomycin
references.citation: Epidemiol Infect. 2011 Sep;139(9):1342-50
references.pmid: 21073764
references.citation: Diagn Microbiol Infect Dis. 2004 Nov;50(3):201-4
references.pmid: 15541606
references.citation: Ann Intern Med. 2003 Jan 21;138(2):135-42
references.pmid: 12529096
references.citation: Antimicrob Agents Chemother. 1986 Oct;30(4):532-5
references.pmid: 3024560
references.citation: J Antimicrob Chemother. 2008 Apr;61(4):838-44
references.pmid: 18230690
references.citation: Infect Control Hosp Epidemiol. 2007 Sep;28(9):1054-9
references.pmid: 17932826
references.citation: Biol Blood Marrow Transplant. 2007 May;13(5):615-21
references.pmid: 17448922
references.citation: Clin Infect Dis. 2012 Apr;54(8):1110-22
references.pmid: 22412055
references.citation: Am J Surg. 1999 May;177(5):418-22
references.pmid: 10365883
references.citation: Diagn Microbiol Infect Dis. 2008 Sep;62(1):81-5
references.pmid: 18508225
references.citation: Science. 1975 Feb 7;187(4175):398-404
references.pmid: 17835295
references.citation: Clin Transplant. 2005 Dec;19(6):711-6
references.pmid: 16313314
references.citation: Clin Ther. 2010 Sep;32(10):1713-9
references.pmid: 21194593
references.citation: Clin Infect Dis. 1996 Oct;23(4):760-6
references.pmid: 8909841
references.citation: Ann Intern Med. 2001 Oct 2;135(7):484-92
references.pmid: 11578151
references.citation: Clin Infect Dis. 2004 Aug 1;39(3):309-17
references.pmid: 15306996
references.citation: Infect Control Hosp Epidemiol. 2008 Nov;29(11):996-1011
references.pmid: 18947320
references.citation: Clin Infect Dis. 2012 Oct;55(8):1114-21
references.pmid: 22744885
references.citation: Support Care Cancer. 2011 Dec;19(12):1969-74
references.pmid: 21110047
references.citation: Infect Control Hosp Epidemiol. 2007 Aug;28(8):983-91
references.pmid: 17620248
references.citation: Infect Control Hosp Epidemiol. 2009 Feb;30(2):184-6
references.pmid: 19125679
references.citation: Infect Control Hosp Epidemiol. 2003 Apr;24(4):251-6
references.pmid: 12725353
references.citation: Clin Infect Dis. 2000 Mar;30(3):466-72
references.pmid: 10722429
references.citation: J Infect Dis. 2005 Feb 15;191(4):588-95
references.pmid: 15655783
references.citation: Antimicrob Agents Chemother. 2012 Feb;56(2):838-44
references.pmid: 22123698
references.citation: J Antimicrob Chemother. 2008 Sep;62 Suppl 1:i17-28
references.pmid: 18684703
references.citation: J Antimicrob Chemother. 2009 Jul;64(1):175-80
references.pmid: 19423543
references.citation: Clin Infect Dis. 2003 Jan 15;36(2):159-68
references.pmid: 12522747
references.citation: J Antimicrob Chemother. 2012 Sep;67(9):2243-9
references.pmid: 22618861
references.citation: Clin Infect Dis. 2008 Jan 1;46(1):30-6
references.pmid: 18171210
references.citation: Biol Blood Marrow Transplant. 2010 Nov;16(11):1576-81
references.pmid: 20685257
references.citation: Pharmacotherapy. 2011 Jun;31(6):527-36
references.pmid: 21923436
references.citation: Clin Infect Dis. 2004 Apr 1;38(7):994-1000
references.pmid: 15034832
references.citation: JAMA. 2000 Apr 19;283(15):2008-12
references.pmid: 10789670
references.citation: Clin Microbiol Infect. 2010 Jun;16(6):555-62
references.pmid: 20569266
references.citation: Diagn Microbiol Infect Dis. 2007 Jun;58(2):163-70
references.pmid: 17368801
references.citation: J Hosp Med. 2012 Mar;7(3):243-8
references.pmid: 22076962
references.citation: Diagn Microbiol Infect Dis. 2000 Mar;36(3):145-58
references.pmid: 10729656
references.citation: Am J Infect Control. 2004 Dec;32(8):470-85
references.pmid: 15573054
references.citation: Ann Pharmacother. 2009 Jul;43(7):1211-9
references.pmid: 19584384